Treatment fields for advanced ovarian cancer fail to prolong OS

The expansion of growth getting fields chemotherapy didn’t delay endurance for ladies with platinum-safe ovarian disease, as per the gadget’s maker.

Growth treating fields [TTFields (Novocure)] are electric fields that are used to apply actual powers to kill disease cells.

They are conveyed by a painless, versatile gadget supported in the US for treatment of glioblastoma or mesothelioma.

The randomized stage 3 ENGOT-ov50/GOG-3029/Advance 3 preliminary included 558 ladies with platinum-safe ovarian disease.

Specialists relegated 280 of them to paclitaxel in addition to TTFields. The other 278 got paclitaxel alone.

The primary endpoint of the study was not met, as there was no statistically significant increase in OS among women assigned to TTFields (median, 12.2 months vs. 11.9 months; HR = 1.008).

TTFields displayed a security profile predictable with earlier examinations.

The preliminary selected ladies who had gotten up to five earlier lines of fundamental treatment. An exploratory investigation recommended a potential endurance benefit for ladies who had gotten just a single earlier line of treatment.

“While the final results of the ENGOT-ov50/GOG-3029/INNOVATE-3 trial differ from our initial expectation, these data add important context to the treatment paradigm,” David O’Malley, MD, professor of obstetrics and gynecology at The Ohio State University Wexner College of Medicine and director of the division of gynecologic oncology at The James Comprehensive Cancer Center, said in a Novocure-issued press release. “We see treatment exposure and number of prior therapies are relevant and can drive outcomes, and we will leverage these data as we explore and identify new opportunities to treat this deadly disease.”